1. Scrip
  2. >>Focus On Asia

US Filing Eyed After Qurient's Novel TB Candidate Proves Mettle

 
• By Jung Won Shin

South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.

Doctor examining at lungs radiograph x-ray film of patient in operation room. medical concept.
Positive Telacebec Results Published In NEJM • Source: Shutterstock

South Korea's Qurient Co. Ltd. has unveiled positive Phase IIb clinical results for telacebec (Q203), its first-in-class, oral antibiotic for the treatment of tuberculosis, which support continued development towards the first universal regimen for the disease regardless of drug resistance status.

Results published in the New England Journal of Medicine show the Phase II study was a randomized, open-label trial in 61 patients with newly diagnosed, rifampicin- and isoniazid-susceptible pulmonary TB

More from South Korea

More from Focus On Asia

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.